Molecular cytogenetics of prostate cancer

Critical Reviews in Oncogenesis

Volumn 7, Issue 3-4, 1996, Pages 143-150

  Koivisto, Pasi A ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Androgen receptor gene; Cancer genetics; Comparative genomic hybridization; Fluorescence in situ hybridization; Prostate carcinoma

Indexed keywords

CANCER GENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; MALE; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

EID: 0030405380     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v7.i3-4.10     Document Type: Review

References (67)

1. Alcaraz, A., S. Takahashi, J. A. Brown, J. F. Herath, E. J. Bergstrahl, J. J. Larson-Keller, M. M. Lieber, and R. B. Jenkins: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are mark- ers of poor prognosis in prostate cancer. Cancer Res., 54:3998-4002 (1994).
2. Anastasi, J., B. M. Le Beau, J. W. Vardman, A. A. Fernals, R. A. Larson, and J. D. Rowley: Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. Blood, 79:1796-1801 (1992).
3. Bandyk, M. G., L. Zhao, P. Troncoso, L. L. Pisters, J. L. Palmer, A. C. von Eschenbach, L. W. K. Chung, and J. C. Liang: Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chrom. Cancer, 9:19-27 (1994).
4. Bergerheim, U. S., V. P. Collins, P. Ekman, and K. Kunimi: Recessive genetic mechanisms in the oncogenesis of prostatic carcinoma. Scand. J. Urol. Nephrol. Suppl., 138:93-96 (1991).
5. Bergerheim U. S. R., K. Kunimi, V. P. Collins, and P. Ekman: Deletion mapping of chromosomes 8, 10, and 16 in human prostatic adenocarcinomas. Genes Chrom. Cancer, 3:215-220 (1991).
6. Boring C. C., T. S. Squires, and T. Tong: Cancer statistics, 1993. CA. Cancer J. Clin., 43:7-26 (1993).
7. Bova, G. S., B. S. Carter, M. J. G. Bussemakers, M. Emi, Y. Fujiwara, N. Kyprianou, S. C. Jacobs, J. C. Robinson, J. I. Epstein, P. C. Walsh, and W. B. Isaacs: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res., 53:3869-3873 (1993).
8. Breitkreuz, T., K. Romanakis, S. Lutz, G. Seitz, H. Bonkhoff, G. Unteregger, T. Zwergel, K. D. Zang, B. Wullich: Genotypic characterization of prostatic carcinomas: a combined cytogenetic, flow cytometry, and in situ DNA hybridization study. Cancer Res., 53:4035-4040 (1993).
9. Brothman, A. R., D. M. Peehl, A. M. Patel, and J. E. McNeal: Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res., 50:3795-3803 (1990).
10. Brothman, A. R., D. M. Peehl, A. M. Patel, G. R. McDonald, J. E. McNeal, L. E. Ladaga, and P. F. Schnellhammer: Cytogenetic evaluation of 20 cultured primary prostatic tumors. Cancer Genet Cytogenet., 55:79-84 (1991).
11. Brothman, A. R., A. M. Patel, D. M. Peehl, and P. F. Schellhammer: Analysis of prostatic tumor cultures using fluorescence in situ hybridization (FISH). Cancer Genet. Cytogenet., 62:180-185 (1992).
12. Brothman, A. R., M. J. Watson, X. L. Zhu, B. J. Williams, and L. R. Rohr: Evaluation of 20 archival prostate tumor specimens by fluorescence in situ hybridization (FISH). Cancer Genet. Cytogenet., 75:40-44 (1994).
13. Casalone, R., P. Portentoso, P. Granata, E. Minelli, E. Righi, E. Meroni, E. Pozzi, and A. M. Chiaravalli: Chromosome changes in benign prostatic hyperplasia and their significance in the origin of prostatic carcinoma. Cancer Genet. Cytogenet., 68:126-130 (1993).
14. Chang, M., K. Tsuchiya, R. H. Batchelor, P. S. Rabinovitch, B. G. Kulander, R. C. Haggitt, and G. C. Burmer: Deletion mapping of chromosome 8p in colorectal carcinoma and dysplasia arising in ulserative colitis, prostatic carcinoma, and malignant fibrous histocytomas. Am. J. Pathol., 144:1-6 (1994).
15. Cher, M. L., D. MacGrogan, R. Bookstein, J. A. Brown, R. B. Jenkins, and R. H. Jensen: Comparative genomic hybridization, allelic imbalance and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chrom. Cancer, 11:153-162 (1994).
16. Cher, M. L., I. Takashi, N. Weinder, P. Carroll, and R. H. Jensen: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J. Urol., 153:249-254 (1995).
17. Cher, M. L., G. S. Bova, D. H. Moore, E. J. Small, P. R. Carroll, S. S. Pin, J. I. Epstein, W. B. Isaacs, R. H. Jensen: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res., 56:3091-3102 (1996).
18. Cho, K. R. and B. Vogelstein: Genetic alterations in the adenocarcinoma sequence. Cancer, (1992).
19. Collard, J. G., M. van de Poll, A. Scheffer, E. Roos, A. H. M. Hopman, A. H. M. Geurts van Kessel, and J. J. M. van Dongen: Location of genes involved in invasion and metastasis on human chromosome 7. Cancer Res., 47:6666-6670 (1987).
20. Elfving, P., J. C. Cigudosa, R. Lundgren, J. Limon, N. Mandahl, U. Kristoffersson, S. Heim, and F. Mitelman: Trisomy 7, trisomy 10 and lloss of the Y chromosome in short-term cultures of normal kidney tissue. Cytogenet. Cell Genet., 53:123-125 (1990).
21. Gittes, R. F.: Carcinoma of the prostate. N. Engl. J. Med., 324:236-245 (1991).
22. Greyhack, J., T. Keeler, and J. Kozlowski: Carcinoma of the prostate: hormonal therapy. Cancer, 60:589-601 (1987).
23. Heim, S., N. Mandahl, Y. Jin, S. Str-mblad, E. Lindstr-m, L. G. Salford, and F. Mitelman: Trisomy 7 and sex chromosome loss in human brain tissue. Cytogenet. Cell Genet., 52:136-138 (1989).
24. Henke, R. P., E. Krüger, N. Ayhan, D. Hübner, and P. Hammerer: Numerical chromosomal aberrations in prostate cancer: correlations with morphology and cell kinetics. Virchows Arch. A Pathol. Anat. Histopathol., 422:61-66 (1993).
25. Hopman, A. H. N., F. C. S. Ramaekers, A. K. Raap, J. L. M. Beck, P. Devilee, M. van der Ploeg, and G. P. Vooijs: In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry, 89:307-316 (1988).
26. Hyytinen, E., T. Visakorpi, A. Kallioniemi, O. P. Kallioniemi, and J. Isola: Improved technique for analysis of formalin-fixed, paraffin embedded tumors by fluorescence in situ hybridization. Cytometry, 16:93-99 (1994).
27. Isola, J., S. DeVries, L. Chu, S. Ghazvini, and F. Waldman: Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am. J. Pathol., 145:1301-1308 (1994).
28. Jacobsen, S. J., S. K. Katusic, E. J. Bergstralh, J. E. Oesterling, D. Ohrt, G. G. Klee, C. G. Chute, and M. Lieber: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J. Am. Med. Assoc., 274:1445-1449 (1995).
29. Jenkins, R. B., M. M. Le Beau, W. J. Kraker, T. J. Borell, P. G. Stalboerger, and E. M. Davis: Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood, 79:3307-3315 (1992).
30. Johansson, B., S. Heim, N. Mandahl, F. Mertens, and F. Mitelman: Trisomy 7 in non-neoplastic cells. Genes Chrom. Cancer, 6:199-205 (1993).
31. Joos, S., U. Bergerheim, Y. Pan, H. Matsuyama, M. Benz, S. du Manoir, and P. Lichter: Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chrom. Cancer, 14:267-276 (1995).
32. Kallioniemi, O.-P., A. Kallioniemi, J. Piper, J. Isola, F. M. Waldman, J. W. Gray, and D. Pinkel: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chrom. Cancer, 10:231-243 (1994).
33. Kallioniemi, A., O.-P. Kallioniemi, D. Sudar, Rutovitz, J. W. Gray, F. Waldman, and D. Pinkel: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 258:818-821 (1992).
34. Klein, L.: Prostatic Carcinoma. N. Engl. J. Med., 300:824 (1979).
35. Koivisto, P., E. Hyytinen, C. Palmberg, T. Visakorpi, T. Tammela, J. Isola, and O.-P. Kallioniemi: FISH analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am. J. Pathol., 147:1608-1614 (1995).
36. Koivisto, P., T. Visakorpi, O.-P. Kallioniemi: Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand. J. Clin. Lab. Invest., 226(Suppl):57-64 (1996).
37. Koivisto, P., J. Kononen, C. Palmberg, E. Hyytinen, T. Tammela, J. Trapman, J. Isola, T. Visakorpi, and O.-P. Kallioniemi: Androgen receptor gene amplification: a possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res., in press (1997).
38. König, J. J., W. Teubel, J. W. van Dongen, A. Hagemeijer, J. C. Romijn, and F. H. Schröder: Tissue culture loss of aneuploid cells from carcinomas of the prostate. Genes Chrom. Cancer, 8:22-27 (1993).
39. König, J. J., W. Teubel, J. W. van Dongen, J. C. Romijn, A. Hagemeijer, and F. H. Schröder: Loss and gain of chromosomes 1, 18 and Y in prostate cancer. Prostate, 25:281-291 (1994).
40. Kovacs, G. and P. Prusa: Clonal chromosome aberrations in normal kidney tissue from patients with renal cell carcinoma. Cancer Genet. Cytogenet., 37:289-290 (1989).
41. Kunimi, K., U. S. P. Bergerheim, I.-L. Larsson, P. Ekman, and V. P. Collins: Allelotyping of human prostatic adenocarcinoma. Genomics, 11:530-536 (1991).
42. Latil, A., J.-C. Baron, O. Cussenot, G. Fournier, L. Boccon-Gibod, A. Le Duc, and R. Lidereau: Oncogene amplifications in early-stage human prostate carcinomas. Int. J. Cancer, 59:637-638 (1994).
43. Ling, V., A. F. Chambers, J. F. Harris, and R. P. Hill: Quantitative genetic analysis of tumor progression. Cancer Metastasis Rev., 4:173-192 (1985).
44. Lundberg, S., J. Cartensen, and I. Rundquist: DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res., 47:1973-1977 (1987).
45. Lundgren, R., N. Mandahl, S. Heim, J. Limon, H. Henrikson, and F. Mittelman: Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chrom. Cancer, 4:16-24 (1992).
46. Lundgren, R.: Cytogenetic studies of prostatic cancer. Scand. J. Urol. Nephrol. Suppl., 136:1-35 (1991).
47. Macoska, J. A., T. M. Trybus, W. A. Sakr, M. C. Wolf, P. D. Benson, I. J. Powell, and J. E. Pontes: Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human chromosome cancer. Cancer Res., 54:3824-3830 (1994).
48. Matsuyama, H., Y. Pan, L. Skoog, B. Tribukait, K. Naito, P. Ekman, P. Lichter, and U. S. R. Bergerheim: Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene, 9:3071-3076 (1994).
49. Micale, M. A., A. Mohamed, W. Sakr , I. J. Powell, and S. R. Wolman: Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. Cancer Genet. Cytogenet., 61:165-173 (1992).
50. Micale, M. A., J. S. Sanford, I. J. Powell, W. A. Sakr, and S. R. Wolman: Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma: paraffin FISH vs. metaphase analysis. Cancer Genet. Cytogenet., 69:7-12 (1993).
51. Monni, O., H. Joensuu, K. Franssila, and S. Knuutila: DNA copy number changes in diffuse large B-cell lymphoma - comparative genomic hybridization study. Blood, 87:5269-5278 (1996).
52. Palmberg, C., P. Koivisto, E. Hyytinen, J. Isola, T. Visakorpi, O.-P. Kallioniemi, and T. Tammela: Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with nonsteroidal pure antiandrogen "Casodex" and favorable response to maximal androgen blockade. Eur. Urol., in press (1996).
53. Philips, S. M. A., D. G. Morton, S. J. Lee, D. M. A. Wallace, and J. P. Neoptelemos: Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16 q in human prostate cancer. Br. J. Urol., 73:390-395 (1994).
54. Potosky, A. L., B. A. Miller, P. C. Albertsen, and B. S. Kramer: The role of increasing detection in the rising incidence of prostate cancer. J. Am. Med. Assoc., 273:548-552 (1995).
55. Qian, J., D. BostwickD, S. Takahashi, T. Borell, J. Herath, M. Lieber, and R. Jenkins: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res., 55:5408-5414 (1995).
56. Scardino, P. T., J. R. Beck, and B. J. Miles: Conservative management of prostate cancer. N. Engl. J. Med., 330:1831 (1994).
57. Stephenson, R. A., C. R. Smart, G. P. Mineau, B. C. James, D. T. Janerich, and R. L. Dibble: The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry. Cancer, 77:1342-1348 (1996).
58. Takahashi, S., J. Qian, J. A. Brown, A. Alcaraz, D. G. Bostwick, M. M. Lieber, and R. B. Jenkins: Potential markers of prostate cancer aggressiviness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res., 2:137-145 (1994).
59. 0) prostate carcinoma. Clin. Cancer Res., 2:137-145 (1996).
60. Trent, J. M., F. L. Meyskens, S. E. Salmon, K. Ryschon, S. P. L. Leong, J. R. Davis, and D. L. McGee: Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N. Eng. J. Med., 322:1508-1511 (1990).
61. United Kingdom Cancer Cytogenetics Group: Loss of Y chromosome from normal and neoplastic bone marrows. Genes Chrom. Cancer, 5:83-88 (1992).
62. Van Den Berg, C., X. Y. Guan, D. Von Hoff, R. Jenkins, M. Bittner, C. Griffin, O. Kallioniemi, T. Visakorpi, J. McGill, J. Herath, J. Epstein, M. Sarosdy, P. Meltzer, and J. Trent: DNA sequence amplification in human prostate cancer identified by chromosome microdissec- tion: potential prognostic implications. Clin. Cancer Res., 1:11-18 (1995).
63. Visakorpi, T., O.-P. Kallioniemi, T. Koivula, and J. Isola: New prognostic factors in prostatic carcinoma. Eur. Urol., 24:438-449 (1993).
64. Visakorpi, T., E. Hyytinen, A. Kallioniemi, J. Isola, and O.-P. Kallioniemi: Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am. J. Pathol., 145:624-630 (1994).
65. Visakorpi, T., A. H. Kallioniemi, A. C. Syvänen, E. R. Hyytinen, R. Karhu, T. Tammela, J. J. Isola, and O.-P. Kallioniemi: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55:142-147 (1995).
66. Waldman, F. M., P. R. Carroll, R. Kerschmann, M. B. Cohen, F. G. Field, and B. H. Mayall: Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res., 51:3807-3813 (1991).
67. Ziztelsberger, H., S. Szücs, H. U. Weier, L. Lehmann, H. Braselmann, S. Enders, A. Schilling, J. Breul, H. Höfler, and M. Bauchinger: Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) on paraffin-embedded tissue sections with centromere-specific DNA probes. J. Pathol., 172:325-335 (1994).